{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:45:32Z","timestamp":1780065932339,"version":"3.54.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> This systematic review analyzes the state-of-art repurposing of the drug tamoxifen (TAM) in the treatment of Duchenne Muscular Dystrophy (DMD), including its mechanism of action, toxicological findings, and past and ongoing clinical trials. A parallel aim of this work was to explore whether evidence exists to support further funding of investigation on TAM treatment for DMD patients with a pivotal trial in young patients. Bringing evidence and answering the scientific question of whether this treatment could improve the quality-of-life of DMD patients is needed to establish guidelines and accelerate access to promising therapies for DMD patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The search was conducted in January 2022 utilizing PubMed. All MeSH terms for \u201cDuchenne Muscular Dystrophy\u201d and \u201ctamoxifen\u201d were used. The inclusion and exclusion criteria were defined according to the PICOS framework.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The included publications all explored the use of TAM with promising outcomes in muscular strength recovery and a decrease in pathology biomarkers. Two reviews recognize TAM as a potential treatment for DMD patients and state that drug repurposing plays a crucial role in the quest for a drug candidate to treat this rare disease.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> According to available data, TAM shows promise as a treatment for DMD, both pharmacologically and clinically. However, published data to date are insufficient to definitively conclude the beneficial effect of TAM on quality-of-life and ultimately survival, particularly in the youngest patients diagnosed with DMD.<\/jats:p>","DOI":"10.3389\/fphar.2022.1030785","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:40:38Z","timestamp":1668580838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy"],"prefix":"10.3389","volume":"13","author":[{"given":"Valeria","family":"Botti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Staedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41536-022-00214-x","article-title":"Tamoxifen treatment ameliorates contractile dysfunction of Duchenne muscular dystrophy stem cell-derived cardiomyocytes on bioengineered substrates","volume":"7","author":"Birnbaum","year":"2022","journal-title":"NPJ Regen. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.nmd.2011.02.016","article-title":"Idebenone as a novel, therapeutic approach for duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial","volume":"21","author":"Buyse","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","article-title":"Progress toward gene therapy for Duchenne muscular dystrophy","volume":"25","author":"Chamberlain","year":"2017","journal-title":"Mol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1479-5876-9-68","article-title":"Improvement of cardiac contractile function by peptide-based inhibition of NF-\u03baB in the utrophin\/dystrophin-deficient murine model of muscular dystrophy","volume":"9","author":"Delf\u00edn","year":"2011","journal-title":"J. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1515\/jpem.2008.21.5.449","article-title":"Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia","volume":"21","author":"Derman","year":"2008","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ajpath.2012.10.018","article-title":"The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy","volume":"182","author":"Dorchies","year":"2013","journal-title":"Am. J. Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/s0960-8966(02)00140-2","article-title":"Survival in duchenne muscular dystrophy: Improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"B9","doi-asserted-by":"crossref","unstructured":"EU\/3\/171\/944: Orphan designation for the treatment of Duchenne muscular dystrophy\n            European Medicines Agency\n          2017","DOI":"10.1007\/978-1-4939-7374-3_12"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7334","DOI":"10.1158\/0008-5472.CAN-05-4269","article-title":"Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome","volume":"66","author":"Frasor","year":"2006","journal-title":"Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2533\/chimia.2018.238","article-title":"Repurposing the selective oestrogen receptor modulator tamoxifen for the treatment of duchenne muscular dystrophy","volume":"72","author":"Gayi","year":"","journal-title":"Chimia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1038\/s41467-018-07058-4","article-title":"Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy","volume":"9","author":"Gayi","year":"","journal-title":"Nat. Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy. A randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","article-title":"Second-generation compound for the modulation of utrophin in the therapy of DMD","volume":"24","author":"Guiraud","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1914171","DOI":"10.1001\/jamanetworkopen.2019.14171","article-title":"Effect of combination l-Citrulline and Metformin treatment on motor function in patients with duchenne muscular dystrophy: A randomized clinical trial","volume":"2","author":"Hafner","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/jrf.0.0130101","article-title":"A new derivative of triphenylethylene: Effect on implantation and mode of action in rats","volume":"13","author":"Harper","year":"1967","journal-title":"J. Reprod. Fertil."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.3390\/ijms21134596","article-title":"Anti-Inflammatory and General glucocorticoid physiology in skeletal muscles affected by duchenne muscular dystrophy: Exploration of steroid-sparing agents","volume":"21","author":"Herbelet","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1016\/j.bmcl.2010.06.151","article-title":"A mutant selective anti-estrogen is a pure antagonist on EREs and AP-1 response elements","volume":"20","author":"Jain","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.steroids.2007.07.009","article-title":"New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer","volume":"72","author":"Jordan","year":"2007","journal-title":"Steroids"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S269","DOI":"10.1038\/sj.bjp.0706399","article-title":"Tamoxifen (ICI46, 474) as a targeted therapy to treat and prevent breast cancer","volume":"147","author":"Jordan","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/0960-0760(91)90292-D","article-title":"Tamoxifen and oestrogen both protect the rat muscle against physiological damage","volume":"40","author":"Koot","year":"1991","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1038\/s41467-018-07057-5","article-title":"Tamoxifen therapy in a murine model of myotubular myopathy","volume":"9","author":"Maani","year":"2018","journal-title":"Nat. Commun."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1007\/s00415-011-5979-z","article-title":"Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up","volume":"258","author":"Magri","year":"2011","journal-title":"J. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The Discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/jnd-210643","article-title":"Open-label evaluation of eteplirsen in patients with duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/cr.2016.28","article-title":"Duchenne muscular dystrophy: CRISPR\/Cas9 treatment","volume":"26","author":"Mendell","year":"2016","journal-title":"Cell Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.expneurol.2005.11.021","article-title":"Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice","volume":"198","author":"Messina","year":"2006","journal-title":"Exp. Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.gendis.2019.12.007","article-title":"Promising therapeutic approaches using CRISPR\/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy","volume":"8","author":"Mollanoori","year":"2021","journal-title":"Genes Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"A phase 1b trial to assess the pharmacokinetics of Ezutromid in Pediatric duchenne muscular dystrophy patients on a Balanced Diet","volume":"8","author":"Muntoni","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s13063-019-3740-6","article-title":"Tamoxifen in duchenne muscular dystrophy (TAMDMD): Study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial","volume":"20","author":"Nagy","year":"2019","journal-title":"Trials"},{"key":"B36","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/s0960-8966(02)00087-1","article-title":"The role of utrophin in the potential therapy of duchenne muscular dystrophy","volume":"12","author":"Perkins","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"B38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2119\/molmed.2010.00263","article-title":"Peptide-based inhibition of NF-\u03baB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy","volume":"17","author":"Peterson","year":"2011","journal-title":"Mol. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1093\/eurheartj\/ehab054","article-title":"Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data","volume":"42","author":"Porcher","year":"2021","journal-title":"Eur. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/cells9122657","article-title":"The failed clinical story of myostatin inhibitors against duchenne muscular dystrophy: Exploring the Biology behind the Battle","volume":"9","author":"Rybalka","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631","article-title":"The burden, epidemiology, costs and treatment for duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/jcph.468","article-title":"Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers","volume":"55","author":"Tinsley","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.nmd.2022.01.007","article-title":"Safety and clinical outcome of tamoxifen in duchenne muscular dystrophy","volume":"31","author":"Tsabari","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3390\/ijms20236053","article-title":". Teaching an old molecule new tricks: Drug repositioning for Duchenne muscular dystrophy","volume":"20","author":"Vitiello","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00418-005-0030-z","article-title":"Oestrogen receptor \u03b2 is present in both muscle fibres and endothelial cells within human skeletal muscle tissue","volume":"124","author":"Wiik","year":"2005","journal-title":"Histochem. Cell Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1030785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T06:40:40Z","timestamp":1668580840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1030785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":43,"alternative-id":["10.3389\/fphar.2022.1030785"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1030785","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"article-number":"1030785"}}